Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

Cited by (785)

Items 401–500 of 785

1. Valsartan impairs angiogenesis of mesenchymal stem cells through Akt pathway
   Cheng‐I Cheng, Chang‐Chun Hsiao, Shinn‐Chih Wu, Shao-Yu Peng, Hon‐Kan Yip, Morgan Fu, Feng‐Sheng Wang · 2012 · International Journal of Cardiology
2. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke
   Chia-Jen Shih, Hung‐Ta Chen, Pei-Wen Chao, Shu‐Chen Kuo, Szu‐Yuan Li, Chih‐Yu Yang, Der‐Cherng Tarng, Shuo‐Ming Ou, Yung‐Tai Chen · 2015 · Journal of Hypertension
3. Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey
   Giuliano Tocci, Arrigo F.G. Cicero, Massimo Salvetti, Beatrice Musumeci, Andrea Ferrucci, Claudio Borghi, Massimo Volpe · 2017 · Clinical Hypertension
4. Angiotensin II Attenuates the Bioactivities of Human Endothelial Progenitor Cells via Downregulation of β2-Adrenergic Receptor
   Seon‐Jin Lee, Da Yeon Kim, Jisoo Yun, Sung Hyun Choi, Seok Yun Jung, Songhwa Kang, Ji‐Hye Park, Yeon Ju Kim, Jong Seong Ha, Seung Taek Ji et al. · 2018 · Stem Cells International
5. Blood pressure, blood pressure variability and the risk of poststroke dementia
   Nina A. Hilkens, Catharina J.M. Klijn, Edo Richard · 2021 · Journal of Hypertension
6. Histopathological Evaluation of Protective Effect of Telmisartan against Radiation-Induced Bone Marrow Injury
   Masoomeh Fooladi · 2022 · Journal of Biomedical Physics and Engineering
7. Value of Angiotensin Receptor Blocker Therapy in Diabetes
   Joseph L. Izzo, Adrienne S. Zion · 2011 · Journal of Clinical Hypertension
8. Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile
   Giacomo Dell’Omo, Giuseppe Penno, Stefano Del Prato, Massimiliano Mariani, Roberto Pedrinelli · 2008 · Journal of Human Hypertension
9. The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
   Dmitry Abramov, Peter E. Carson · 2012 · Journal of the Renin-Angiotensin-Aldosterone System
10. Complicaciones microvasculares de la diabetes
    Belén Pérez‐Pevida, María Llavero, Javier Gargallo, Javier Escalada · 2016 · Medicine - Programa de Formación Médica Continuada Acreditado
11. Disturbances of gait and postural stability in chronic cerebral ischemia
    N.N. Vakhnina, Vladimir Vladimirovich Zakharov · 2017 · S S Korsakov Journal of Neurology and Psychiatry
12. Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada
    Calvin Ke, Steve Morgan, Kate Smolina, Danijela Gašević, Hong Qian, Nadia A. Khan · 2017 · BMJ Open
13. Blood Pressure and Diabetic Nephropathy
    Zachary T. Bloomgarden · 2010 · Diabetes Care
14. Optimizing exercise prescription for blood pressure control after stroke or transient ischemic attack: A systematic review and meta-analysis
    Yifan Zhang, Hao Huang, Zhiyuan Tan, Lingzi Lei, Xueying Chen · 2026 · Preventive Medicine
15. Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers
    Nikitas Georgiou, Eleni Chontzopoulou, Efthymios Alexandros Routsi, Iren Georgia Stavrakaki, Errikos Petsas, Nikoletta Zoupanou, Margarita Georgia Kakava, Demeter Tzeli, Thomas Mavromoustakos, Sofia Kiriakidi · 2024 · ACS Omega
16. Optimizing Vascular Risk Reduction in the Stroke Patient with Atherothrombotic Disease
    Bruce I Ovbiagele · 2009 · Medical Principles and Practice
17. Albuminuria in relation to the single and combined effects of systolic and diastolic blood pressure in Chinese
    Chang‐Sheng Sheng, Ming Liu, Jun Zou, Qi‐Fang Huang, Yan Li, Ji‐Guang Wang · 2012 · Blood Pressure
18. Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients)
    Ludwin Ley, Helmut Schumacher · 2012 · Current Medical Research and Opinion
19. Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
    Yara Wanas, Rim Bashir, Nazmul Islam, Luis Furuya‐Kanamori · 2020 · BMC Cardiovascular Disorders
20. 2021 Taiwan Stroke Society Guidelines of blood pressure control for ischemic stroke prevention
    Nai‐Fang Chi, Chih‐Ping Chung, Hao-Ming Cheng, Chi‐Hung Liu, Chun‐Jen Lin, Li‐Chi Hsu, Sung‐Chun Tang, Jiunn‐Tay Lee, Helen L. Po, Jiann‐Shing Jeng et al. · 2022 · Journal of the Chinese Medical Association
21. Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents?
    Pedro Armario, Alejandro de la Sierra · 2009 · Therapeutic Advances in Cardiovascular Disease
22. Prevention of stroke: new evidence
    B. Dahlöf · 2009 · European Heart Journal Supplements
23. Dual blockade of the renin-angiotensin system: are two better than one?
    Richard Haynes, Phil D Mason, Kazem Rahimi, Martin Landray · 2009 · Nephrology Dialysis Transplantation
24. Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke
    Ichiro Deguchi, Daisuke Furuya, Takuya Fukuoka, Norio Tanahashi · 2012 · Hypertension Research
25. Management of Chronic Hypertension Following Intracerebral Hemorrhage
    Edward T. Van Matre, Aaron M. Cook, Samarth P. Shah, Alexandria C. Rydz, Keaton S. Smetana · 2019 · Critical Care Nursing Quarterly
26. Protective effects of renin–angiotensin blockade beyond blood pressure control
    Giuseppe Mancia, Cristina Giannattasio, Gino Seravalle, Fosca Quarti‐Trevano, Guido M. Grassi · 2009 · Journal of Human Hypertension
27. Temas de actualidad en hipertensión arterial y diabetes
    Pilar Mazón‐Ramos, Alberto Cordero, Juan Quiles, Josep Guindo Soldevila · 2009 · Revista Española de Cardiología
28. What do the results of the PRoFESS trial teach us?
    Graeme J. Hankey, John W. Eikelboom · 2008 · The Lancet Neurology
29. RETRACTED ARTICLE: Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil
    Fereshteh Asgharzadeh, Niloufar Naghibzadeh, Milad Hashemzehi, Asma Mostafapour, Seyed Mahdi Hassanian, Amir Avan, Majid Khazaei · 2022 · Journal of Gastrointestinal Cancer · Retracted
30. Randomised controlled trials of antihypertensive therapy: does exclusion of orthostatic hypotension alter treatment effect? A systematic review and meta-analysis
    Catriona Reddin, Robert Murphy, Caoimhe Hanrahan, Elaine A. Loughlin, John P. Ferguson, Conor S. Judge, R Waters, Michelle D. Canavan, Rose Anne Kenny, Martin James O'Donnell · 2023 · Age and Ageing
31. Antihypertensive strategies for the prevention of secondary stroke: a systematic review and meta-analysis
    ChunQi Wang, Ling Feng, ShuangYan Tu, Dan Wei, Rui Wang, ZhiQiang Deng, YiPing Luo · 2025 · European journal of medical research
32. Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy
    Bodh I. Jugdutt · 2014 · Springer eBooks
33. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials
    W.J. Elliott · 2012 · Yearbook of Cardiology
34. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku
    Kardiologia Polska Suplement · 2013 · Kardiologia Polska
35. Blood pressure control and impact on cardiovascular events in patients with type 2 diabetes mellitus: A critical analysis of the literature
    Hernando Vargas‐Uricoechea, Manuel Felipe Cáceres-Acosta · 2018 · Clínica e Investigación en Arteriosclerosis (English Edition)
36. The role of angiotensin receptor blockers in CVD risk management
    Leonardo Grabinski Bottino, Flávio Danni Fuchs · 2020 · Expert Review of Cardiovascular Therapy
37. Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines
    Stefano Omboni, Ettore Malacco, Jean-Michel Mallion, Massimo Volpe · 2015 · Clinical Interventions in Aging
38. Management of risk factors for accelerated atherosclerosis
    Sarah Y. Song, Bruce I Ovbiagele · 2009 · Current Treatment Options in Neurology
39. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention
    Robert L. Talbert · 2010 · Journal of the American Pharmacists Association
40. The importance urine albumin-creatinine ratio in the diagnosis and prognosis of chronic kidney disease
    Chester H. Fox, K Neuhaus, JA Vassalotti · 2013 · OA Nephrology
41. Impact of new clinical trials on recent guidelines on hypertension management
    Giuseppe Mancia, Guido M. Grassi · 2011 · Annals of Medicine
42. RAAS inhibition and mortality in hypertension: from pharmacology to clinical evidence.
    Roberto Ferrari · 2013 · PubMed
43. Effect of antihypertensive treatment in isolated systolic hypertension (ISH) – systematic review and meta-analysis of randomised controlled trials
    Mattias Brunström, Bo Carlberg, Sverre Erik Kjeldsen · 2023 · Blood Pressure
44. Understanding the PRoFESS study for secondary stroke prevention
    Michael J. Schneck · 2009 · Current Treatment Options in Cardiovascular Medicine
45. Blood pressure variability and white matter hyperintensities after ischemic stroke
    Nina A. Hilkens, Frank‐Erik de Leeuw, Catharina J.M. Klijn, Edo Richard · 2024 · Cerebral Circulation - Cognition and Behavior
46. Comparative efficacy of different antihypertensive drug classes for stroke prevention: A network meta-analysis of randomized controlled trials
    Ding Yu, Junxia Li, Yuan Cheng, Handong Wang, Xindi Ma, Tao Ding, Zhong‐ning Zhu · 2025 · PLoS ONE
47. Effect of Telmisartan on Cerebral and Systemic Haemodynamics in Patients with Recent Ischaemic Stroke: A Randomised Controlled Trial
    Gillian M. Sare, Andrew Ghadami, Sandeep Ankolekar, Timothy J. England, Fiona Hammonds, Margaret Adrian, Judith Clarke, Lynn Stokes, Dorothee P. Auer, Philip M. Bath · 2013 · ISRN Stroke
48. Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trials
    Guido M. Grassi, Giuseppe Mancia · 2009 · Journal of Hypertension
49. Hypertension 2010: what was new for the cardiologist?
    Zbigniew A. Gaciong, Bartosz Symonides · 2010 · Expert Opinion on Pharmacotherapy
50. Blood pressure-lowering treatment for primary and secondary prevention of different types of stroke
    Hisatomi Arima · 2009 · Expert Review of Cardiovascular Therapy
51. Neurological disorders in hypertensive patients
    Вахнина Наталья Васильевна, O. V. Milovanova, V. V. Grinyuk · 2015 · Neurology neuropsychiatry Psychosomatics
52. Valsartan and Telmisartan Abrogate Angiotensin II–induced Downregulation of ABCA1 Expression Via AT1 Receptor, Rather than AT2 Receptor or PPARγ Activation
    Hongying Chen, Zhen Xu, Lianfeng Chen, Wei Wang, Quan Fang, Xiaowei Yan · 2012 · Journal of Cardiovascular Pharmacology
53. Pharmacologic Management of Hypertension
    Joseph J. Saseen · 2012 · Elsevier eBooks
54. Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Juan Pablo Domecq, Gabriela J. Prutsky, Tarig A. Elraiyah, Zhen Wang, Karen F. Mauck, Juan Pablo Brito, Chaitanya Undavalli, Vishnu Sundaresh, Larry J. Prokop, Víctor M. Montori et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
55. The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome
    Robert G. Krysiak, Marcin Basiak, Witold Szkróbka, Bogusław Okopień · 2021 · The Journal of Clinical Pharmacology
56. Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PRoFESS trial
    Guido M. Grassi, Fosca Quarti‐Trevano, Raffaella Dell’Oro, Giuseppe Mancia · 2009 · Current Hypertension Reports
57. Role of renin–angiotensin system inhibitors in retardation of progression of end-stage renal failure: a retrospective study
    Tomoyuki Murakami, Tamio Iwamoto, Gen Yasuda, Michiko Taniguchi, Akira Fujiwara, Nobuhito Hirawa, Satoshi Umemura · 2015 · Clinical and Experimental Nephrology
58. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice
    Bertram Pitt · 2009 · Heart
59. Combination therapy in the extended cardiovascular continuum
    Claudio Borghi, Martino Morbini, Arrigo F.G. Cicero · 2015 · Journal of Cardiovascular Medicine
60. Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser1179Dephosphorylation
    Du‐Hyong Cho · 2019 · Journal of Korean Medical Science
61. Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study
    Xinyi Peng, Michael Hecht Olsen, Manan Pareek, Jingjing Bai, Yang Liu, Qirui Song, Jun Cai · 2025 · BMC Medicine
62. Update of the Korean Clinical Practice Guidelines for Stroke: Blood Pressure Management
    Hye Seon Jeong, Hong‐Kyun Park, Jong‐Moo Park, Sang‐Bae Ko, Woo‐Keun Seo, Sung Hyuk Heo, Mi Sun Oh, Joon‐Tae Kim, Hae‐Young Lee, Sungha Park et al. · 2025 · Journal of Clinical Neurology
63. The Efficacy of Antihypertensive Drugs in Lowering Blood Pressure and Cardiovascular Events in the Elderly Population: A Systematic Review and Meta-Analysis
    Raheel Chaudhry, Yusuf A. Siddique, Ahmad Sebai, Mustafa Moazam, Ghazala S. Virk, Yonas Tamene, Mohamed Hassouba · 2024 · Cureus
64. Design of trials in lacunar stroke and cerebral small vessel disease: review and experience with the LACunar Intervention Trial 2 (LACI-2)
    Gordon W. Blair, Jason P. Appleton, Iris Isheanesu Mhlanga, Lisa Jane Woodhouse, Fergus Doubal, Philip M. Bath, Joanna Marguerite Wardlaw · 2024 · Stroke and Vascular Neurology
65. Are there new threshold and goals in the treatment of arterial hypertension?
    J. Segura, Luis Miguel Ruilope · 2012 · European Journal of Clinical Investigation
66. Contemporary Management of Transient Ischemic Attack: Role of the Pharmacist
    Denise H. Rhoney · 2011 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
67. Capítulo 5 - Decisão e Metas Terapêuticas
    Marcus Vinícius Bolívar Malachias, WKSB Souza, Frida Liane Plavnik, CIS Rodrigues, AA Brandão, Mário Fritsch Neves, Luiz Aparecido Bortolotto, RJS Franco, CEP Figueiredo, PCBV Jardim et al. · 2016 · Arquivos Brasileiros de Cardiologia
68. Impact of aortic rather than brachial pulsatile haemodynamics on variations in end-organ measures across the full adult blood pressure range
    Bryan Hodson, Gavin Robert Norton, Imraan Ballim, Carlos D. Libhaber, Pinhas Sareli, Angela J. Woodiwiss · 2017 · Journal of Hypertension
69. Effects of anti-hypertensive treatment on major cardiovascular events in populations within prehypertensive levels: a systematic review and meta-analysis
    Zhongqiu Hong, Tao Wu, Shuxian Zhou, Boshui Huang, Jingfeng Wang, Dongmei Jin, Deng-feng Geng · 2018 · Journal of Human Hypertension
70. Stage A: Can Heart Failure Be Prevented?
    Ilya M. Danelich, Brent N. Reed, Carla A. Sueta · 2014 · Current Cardiology Reviews
71. Imbalances in the elderly
    Maksim Valeryevich Zamergrad · 2012 · Neurology neuropsychiatry Psychosomatics
72. Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention
    Carmine Savoia, Lidia Sada, Massimo Volpe · 2015 · Current Hypertension Reports
73. Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008
    Patrick Müller, Stephan Rosenkranz, Oliver Adam, Florian Custodis, Michael Böhm · 2008 · Clinical Research in Cardiology
74. Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan
    Thomas Unger · 2012 · ISRN Vascular Medicine
75. Secondary prevention of stroke: Pleiotropic effects of optimal oral pharmacotherapy
    Kiyoshi Kikuchi, Koichi Kawahara, Naoki Miura, Takashi Ito, Yoko Morimoto, Salunya Tancharoen, Nobuyuki Takeshige, Hisaaki Uchikado, Rokudai Sakamoto, Naohisa Miyagi et al. · 2012 · Experimental and Therapeutic Medicine
76. Selecting antihypertensive medication in patients with essential hypertension in Malaysia.
    Hean Teik Ong, G Rozina · 2009 · PubMed
77. Effects of Neuroprotectants Before and After Stroke: Statins and Anti-hypertensives
    Roberto Federico Villa, Federica Ferrari, Antonio Moretti · 2017 · Springer series in translational stroke research
78. Angiotensin-receptor blockade, cancer, and concerns
    Vivencio Barrios, Carlos Escobar · 2010 · The Lancet Oncology
79. Agreement Between Mega-Trials and Smaller Trials
    Lum Kastrati, Hamidreza Raeisi‐Dehkordi, Erand Llanaj, Hugo G. Quezada‐Pinedo, Farnaz Khatami, Noushin Sadat Ahanchi, Adea Llane, Renald Meçani, Taulant Muka, John P. A. Ioannidis · 2024 · JAMA Network Open
80. Antihypertensive Medication Class and Functional Outcomes After Nonlobar Intracerebral Hemorrhage
    Mohamed Ridha, James Francis Burke, Padmini Sekar, Daniel Woo, Yousef Hannawi · 2025 · JAMA Network Open
81. Association between antihypertensive treatment, blood pressure variability, and stroke severity and outcomes in acute ischemic stroke
    Anastasia Karagiannaki, Nikolaos Kakaletsis, Ioanna Chouvarda, Vasiliki Dourliou, Haralampos J. Milionis, Christos G. Savopoulos, George Ntaios · 2024 · Journal of Clinical Neuroscience
82. Blood pressure targets, medication considerations and special concerns in elderly hypertension III: Focus on stroke and neurodegenerative disorders
    Cheng‐Hsuan Li, Sung‐Ju Hsueh, Li‐Kai Tsai, Wei Hung Chang, Shao‐Yi Cheng, Hao‐Min Cheng, Chih‐Fan Yeh, Yen-Hung Lin, Hsin-hsi C Tsai · 2025 · Journal of the Formosan Medical Association
83. Newer Is Not Always Better: All Antihypertensive Medications Do Not Equally Reduce Cardiovascular Risk
    Gerald W. Smetana · 2012 · Journal of General Internal Medicine
84. Management of blood pressure in acute stroke
    J. Goodfellow, J. Dawson, T. Quinn · 2013 · Expert Review of Neurotherapeutics
85. Lung cancer risk and the inhibitors of angiotensinconverting enzyme: A mini-review of recent evidence
    Masoumeh Asgharpour, Mohammad Ebrahimi Kalan, Seyed Hadi Mirhashemi, Amirhesam Alirezaei · 2019 · Immunopathologia Persa
86. Comparative analysis of hemodialysis and peritoneal dialysis on the risk of new onset diabetes mellitus
    Yung‐Tai Chen, Chih‐Ching Lin, Po-Hsun Huang, Szu‐Yuan Li · 2024 · Journal of the Formosan Medical Association
87. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
    A.A. Rabinstein · 2009 · Yearbook of Neurology and Neurosurgery
88. Morphological and Morphometric Study of Vermian Fossa
    Rakesh Kumar Gupta, Archana Singh · 2017 · International Journal of Advanced and Integrated Medical Sciences
89. Metas de control de la presión arterial e impacto sobre desenlaces cardiovasculares en pacientes con diabetes mellitus tipo 2: un análisis crítico de la literatura
    Hernando Vargas‐Uricoechea, Manuel Felipe Cáceres-Acosta · 2018 · Clínica e Investigación en Arteriosclerosis
90. INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
    Сергей Валентинович Столов · 2020 · Eurasian heart journal
91. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China.
    Si‐qi Lyu, Yanmin Yang, Jun Zhu, Juan Wang, Shuang Wu, Jiameng Ren, Han Zhang, Xing‐hui Shao · 2020 · Europe PMC (PubMed Central)
92. Design of the BEST‐II Randomized Clinical Trial
    Eva A. Mistry, Kimberly Ward Hart, Taylor Davis, Sharon D. Yeatts, Christopher John Lindsell, Roger J. Lewis, Gregory W. Albers, Jonathan P. Wanderer, Charles Joseph Prestigiacomo, Gordon R. Bernard et al. · 2022 · Stroke Vascular and Interventional Neurology
93. Optimum Blood Pressure Target After Lacunar Stroke
    Graeme J. Hankey, Ben Lacey · 2014 · Hypertension
94. Arterial hypertension and atrial fibrillation: selecting antihypertensive therapy
    Jiri Widimsky Jr. · 2012 · Cor et Vasa
95. Physical Activity and Exercise Engagement in Patients Diagnosed with Transient Ischemic Attack and Mild/Non-disabling Stroke: A Commentary on Current Perspectives
    James Faulkner, Lee R. Stoner, Danielle Lambrick · 2014 · Rehabilitation Process and Outcome
96. ARE ACE-INHIBITORS OR ARB’S STILL NEEDED FOR CARDIOVASCULAR PREVENTION IN HIGH RISK PATIENTS? INSIGHTS FROM PROFESS AND TRANSCEND
    W. Van Mieghem, Jean-Marie Billiouw, Christian Brohet, Alain G. Dupont, Marie‐Dominique Gazagnes, F. Heller, Jean-Marie Krzesinski, Luc H. Missault, Alexandre Persu, Luc Piérard et al. · 2010 · Acta Clinica Belgica
97. The Management of Hypertension With Angiotensin Receptor Blockers in Special Populations
    Keith C. Ferdinand, Cheryl Taylor · 2009 · Clinical cornerstone
98. Pharmaceutical Modulation of the Renin Angiotensin Aldosterone System for Stroke Prevention: A Review of Experimental and Clinical Evidence
    Elisavet Moutzouri, George Daios, Moses Elisaf, Haralampos J. Milionis · 2010 · CNS Spectrums
99. Measuring Treatment Effects in Clinical Trials Using Cardiac MRI
    Suzanne de Waha, Georg Friedrich Fuernau, Ingo Eitel, Philipp C. Lurz, Steffen Desch, Gerhard C Schuler, Hölger Thiele · 2011 · Current Cardiovascular Imaging Reports
100. Slaying the CVD dragon with steroids: Figure 1–
     Don D. Sin, Stephan F. van Eeden, S. F. Paul Man · 2010 · European Respiratory Journal